255 related articles for article (PubMed ID: 2785254)
1. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
3. Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission.
Dabholkar M; Advani S; Tatake R; Gangal S
Leuk Res; 1986; 10(2):203-9. PubMed ID: 3456474
[TBL] [Abstract][Full Text] [Related]
4. Studies on natural killer cells in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake RJ; Advani S; Gangal SG
Neoplasma; 1990; 37(1):47-53. PubMed ID: 1690865
[TBL] [Abstract][Full Text] [Related]
5. Modulatory effect of cytokines on natural killer and antibody dependent cellular cytotoxicity directed to squamous cell carcinoma targets by lymphocytes from oral cancer patients.
Desai SA; Maniar HS; Rao RS; Fakih AR; Gangal SG
Eur J Cancer B Oral Oncol; 1993 Jan; 29B(1):69-73. PubMed ID: 8180580
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells.
Chang WC; Fujimiya Y; Casteel N; Pattengale P
Int J Cancer; 1989 Apr; 43(4):591-7. PubMed ID: 2522912
[TBL] [Abstract][Full Text] [Related]
7. Antibody dependent cellular cytotoxicity and complement mediated cytotoxicity on leukemic cells mediated by anti K562 monoclonal antibodies.
Tatake RJ; Maniar HS; Chiplunkar SV; Somasundaram R; Amin MK; Saikia T; Gangal SG
J Clin Lab Immunol; 1990 Feb; 31(2):87-91. PubMed ID: 1966990
[TBL] [Abstract][Full Text] [Related]
8. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
9. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.
Rajaram N; Tatake RJ; Advani SH; Naik SL; Gangal SG
Cancer Immunol Immunother; 1990; 31(1):44-8. PubMed ID: 2306755
[TBL] [Abstract][Full Text] [Related]
10. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation.
Tomescu C; Tebas P; Montaner LJ
AIDS; 2017 Mar; 31(5):613-622. PubMed ID: 28225449
[TBL] [Abstract][Full Text] [Related]
11. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
[TBL] [Abstract][Full Text] [Related]
12. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
[TBL] [Abstract][Full Text] [Related]
13. Modulation of human natural killer cell activity by recombinant human interleukin 2.
Shaw AR; Bleackley RC; Merryweather JP; Barr PJ
Cell Immunol; 1985 Feb; 90(2):547-54. PubMed ID: 3881192
[TBL] [Abstract][Full Text] [Related]
14. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
[TBL] [Abstract][Full Text] [Related]
15. The role of natural killer cells in the treatment of chronic myeloid leukemia.
Silla LM; Whiteside TL; Ball ED
J Hematother; 1995 Aug; 4(4):269-79. PubMed ID: 7489141
[TBL] [Abstract][Full Text] [Related]
16. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
Pierson BA; Miller JS
Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
18. Regulation of natural killer cytotoxicity by Escherichia coli-derived human interferon gamma.
Platsoucas CD
Scand J Immunol; 1986 Jul; 24(1):93-108. PubMed ID: 3088722
[TBL] [Abstract][Full Text] [Related]
19. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
20. Immunological effects of interferon-alpha on chronic myelogenous leukemia.
de Castro FA; Palma PV; Morais FR; Simões BP; Carvalho PV; Ismael SJ; Lima CP; Voltarelli JC
Leuk Lymphoma; 2003 Dec; 44(12):2061-7. PubMed ID: 14959848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]